Table 1.
Comparisons of patients’ clinicodemographic characteristics between transarterial chemoembolization plus sorafenib and transarterial chemoembolization alone groups
| Characteristic | TACE plus Sorafenib (n=56) | TACE alone (n=112) | P |
|---|---|---|---|
| Age (years), mean±SD | 60.7±10.3 | 60.7±10.3 | 1.000 |
| Sex, n (%) | |||
| Male | 42 (75.0) | 91 (81.3) | 0.421 |
| Female | 16 (25.0) | 21 (18.2) | |
| Vascular invasion, n (%) | |||
| Yes | 14 (25.0) | 21 (18.8) | 0.421 |
| No | 42 (75.0) | 91 (81.2) | |
| Number of nodules, n (%) | |||
| Single | 48 (85.7) | 89 (79.5) | 0.401 |
| Multiple-diffuse | 8 (14.3) | 23 (20.5) | |
| Extrahepatic metastasis, n (%) | |||
| Yes | 10 (17.9) | 24 (21.4) | 0.686 |
| No | 46 (82.1) | 88 (78.6) | |
| Tumor size (cm) | |||
| ≤5 | 22 (39.3) | 28 (25.0) | 0.073 |
| >5 | 34 (60.7) | 84 (75.0) | |
| BCLC staging | |||
| 0 | 1 (1.7) | 0 | 0.136 |
| A | 3 (5.4) | 8 (7.1) | |
| B | 16 (28.6) | 19 (17.0) | |
| C | 27 (48.2) | 53 (47.3) | |
| D | 9 (16.1) | 32 (28.6) | |
| Liver cirrhosis | |||
| Yes | 50 (89.3) | 97 (86.6) | 0.805 |
| No | 6 (10.7) | 15 (13.4) | |
| Child-Pugh score | |||
| A | 39 (69.6) | 41 (36.6) | 1.000 |
| B | 14 (25.0) | 47 (42.0) | |
| C | 3 (5.4) | 24 (21.4) | |
| AFP (ng/mL) | |||
| <400 | 37 (69.6) | 67 (59.8) | 0.501 |
| ≥400 | 19 (30.4) | 45 (40.2) | |
| Hepatitis B surface antigen | |||
| Positive | 37 (66.1) | 76 (67.8) | 0.862 |
| Negative | 19 (33.9) | 36 (32.2) | |
| Anti-hepatitis C virus | |||
| Positive | 15 (26.8) | 29 (25.9) | 1.000 |
| Negative | 41 (73.2) | 83 (74.1) |
TACE: Transarterial chemoembolization, BCLC: Barcelona clinic liver cancer, AFP: Alpha-fetoprotein levels, SD: Standard deviation